Ligand Pharmaceuticals Incorporated

Healthcare · Biotechnology

303.00$ +0.1% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Balance Sheet

Ligand Pharmaceuticals Incorporated (LGND) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 2,186 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet LGND
Line item	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	769	787	914	866	955	942	905	949	1,477	1,561	1,532	2,186
Current Assets	254	237	369	312	309	332	309	353	754	832	865	1,457
Cash	19	23	50	18	64	72	48	68	139	175	115	1,007
Cash & Short-Term Investments	191	170	311	227	220	256	209	255	665	734	779	1,358
Receivables	36	39	28	37	42	42	43	42	58	61	55	70
Inventory	25	24	21	14	13	14	12	13	12	9.1	13	10
Goodwill	104	103	105	105	105	105	102	102	102	102	102	102
Intangible Assets	321	300	291	283	275	267	258	250	234	422	411	209
Total Liabilities	101	86	107	91	114	111	110	120	527	543	535	1,218
Current Liabilities	16	17	18	19	25	37	59	65	31	37	41	47
Short-Term Debt	0.5	0.4	1.0	1.2	1.1	1.3	0.9	1.1	1.1	1.1	1.1	1.1
Accounts Payable	2.5	2.4	1.9	1.8	4.7	5.2	5.4	8.6	28	3.2	5.3	9.4
Long-Term Debt	–	–	–	–	–	–	–	–	445	446	447	1,127
Shareholders' Equity	668	701	807	775	841	830	796	829	950	1,017	997	968
Retained Earnings	485	503	589	537	530	499	457	461	578	608	595	583
Shares Outstanding	17	18	18	18	18	19	19	20	20	21	20	22

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings